within Pharmacolibrary.Drugs.N_NervousSystem.N07X_OtherNervousSystemDrugs.N07XX21_Eplontersen;
model Eplontersen 
   extends Pharmacolibrary.Drugs.ATC.N.N07XX21;

  annotation(Documentation(
    info ="<html><body><p>Eplontersen is an antisense oligonucleotide inhibitor of transthyretin (TTR) synthesis, aiming to reduce serum TTR protein levels. It is developed for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy in adults. In 2023, Eplontersen (brand name Wainua) was granted FDA approval for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for subcutaneous administration in adult patients; no peer-reviewed publication with detailed PK model found as of June 2024.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Eplontersen;
